A Phase 3 interventional study of Idelalisib in Chronic Lymphocytic Leukemia, sponsored by Gilead Sciences. Terminated at 45 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-20.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 1 under way, none of them phase 3. idelalisib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by enrollment, is one of 5 that started in 2012, is one of 8 in phase 3, and was the 6th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
idelalisib: first FDA approval 2014 (ZYDELIG), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 8 · Phase 4 1
First in 2008; this study’s year is marked. 5 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 161 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 102 across the 25 interventional studies. Of the 22 that completed or were terminated, 21 (95%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 7 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences: none open now, none under way, none of them phase 3. Of 32 finished, 22 (69%) have results posted.
Among the 36 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Gilead Sciences, this one is the 11th largest by enrollment of the 35 interventional ones that give a count, is one of 7 that started in 2012, is one of 9 in phase 3, and was the 12th registered.
Gilead Sciences’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 1997.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing idelalisib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 36 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this extension study (GS-US-312-0117) that is a companion study to Study GS-US-312-0116 (NCT01539512), is to evaluate the effect of idelalisib on the onset, magnitude, and duration of tumor control. Randomization was done in study GS-US-312-0116, and carried forward to study GS-US-312-117.
Key Inclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Participants will receive idelalisib 300 mg twice daily (600 mg per day).
Drug: Idelalisib
Participants will receive idelalisib 150 mg twice daily (300 mg per day)
Drug: Idelalisib
Idelalisib tablet(s) administered orally twice daily
Also known as: Zydelig®, GS-1101, CAL 101
Progression-Free Survival (PFS)
PFS was defined as the interval from the start of study therapy to the earlier of the first documentation of definitive disease progression or death from any cause; definitive disease progression is chronic lymphocytic leukemia (CLL) progression based on standard criteria other than lymphocytosis alone. PFS was analyzed using Kaplan-Meier (KM) estimates.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Safety: Percentage of Participants With Any Treatment-Emergent Adverse Events (TEAE), ≥ Grade 3 TEAE, Study Drug-Related TEAE, ≥ Grade 3 Study Drug-Related TEAE, Serious TEAE, Study Drug-Related Serious TEAE, and TEAE Leading to Study Drug Discontinuation
The TEAEs were defined as events in a given study period that met one of the following criteria: * Events with onset dates on or after the start of treatment and up to 30 days after the permanent discontinuation of the study treatment. * The continuing adverse events (AEs) diagnosed prior to the start of treatment and worsened in severity grade, or non-serious AEs at baseline which became serious, or AEs resulting in treatment discontinuation after the start of treatment. The severity of AEs was graded by the investigator according to the common terminology criteria for adverse events (CTCAE), Version 4.03, whenever possible. The relationship of an AE to study drug (idelalisib) was assessed using clinical judgment by the investigator, describing the event as either unrelated or related. Events for which the investigator did not record relationship to study drug were considered related to study drug.
Time frame: First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months) plus 4 weeks
Overall Response Rate (ORR)
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). The determination of CLL response and progression were based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs. CR and PR are defined in Protocol Amendment 9, Sections 7.5.1 and 7.5.2.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Lymph Node Response Rate
Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Complete Response (CR) Rate
CR rate was defined as the percentage of participants who achieved a CR (full definition in Protocol Amendment 9, Section 7.5.1). The determination of CLL response and progression were based on standardized IWCLL criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Time to Response (TTR)
TTR was defined as the time interval from start of study therapy to the first documentation of CR or PR.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Duration of Response (DOR)
DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause. DOR was analyzed using KM estimates.
Time frame: From first documentation of CR or PR to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Best Percent Change in Lymph Node Area
The best percent change from baseline in lymph node area (SPD) was defined as the largest decrease in tumor size during the study. The baseline SPD was the last value prior to the baseline reference date. For the participants who only had increases in tumor size from baseline, the smallest increase was considered as the best change from baseline in SPD.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Splenomegaly Response Rate
Splenomegaly response rate was defined as the percentage of participants with baseline splenomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the enlargement of the splenic longest vertical dimension (LVD) (by imaging).
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Hepatomegaly Response Rate
Hepatomegaly response rate was defined as the percentage of participants with baseline hepatomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the hepatic LVD (by imaging).
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Absolute Lymphocyte Count (ALC) Response Rate
ALC response rate was defined as the percentage of participants with baseline lymphocytosis (ALC ≥ 4 x 10\^9 cells/L) who achieved an on-study ALC \< 4 x 10\^9 cells/L or demonstrated a ≥ 50% decrease in ALC from baseline; ALC values within 4 weeks post-baseline were excluded from the ALC response rate evaluation.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Platelet Response Rate
Platelet response rate was defined as the percentage of participants with baseline thrombocytopenia (platelet count \< 100 x 10\^9/L) who achieved an on-study platelet count ≥ 100 x 10\^9/L or demonstrated a ≥ 50% increase in platelet count from baseline; platelet values within 4 weeks post-baseline or after 8 days post transfusion were excluded from the platelet response rate evaluation.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Hemoglobin Response Rate
Hemoglobin response rate was defined as the percentage of participants with baseline anemia (hemoglobin \< 110 g/L \[11.0 g/dL\]) who achieved an on-study hemoglobin ≥ 110 g/L (11.0 g/dL) or demonstrated a ≥ 50% increase in hemoglobin from baseline; hemoglobin values within 4 weeks post-baseline or after 4 weeks of receiving packed cell/whole blood transfusion or after 6 weeks of receiving exogenous growth factors (eg, darbepoetin alfa) were excluded from the hemoglobin response evaluation.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Neutrophil Response Rate
Neutrophil response rate was defined as the percentage of participants with baseline neutropenia (absolute neutrophil count \[ANC\] ≤ 1.5 x 10\^9/L) who achieved an ANC \> 1.5 x 10\^9/L or demonstrated a ≥ 50% increase in ANC from baseline; ANC values within 4 weeks of post-baseline or after 2 weeks of receiving exogenous growth factors (eg, filgrastim, granulocyte-colony stimulating factor \[G-CSF\], lenograstim) or after 4 weeks of receiving Neulasta® were excluded from response evaluation.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Overall Survival
Overall survival was defined as the time interval from start of study therapy to death from any cause. Overall survival was analyzed using KM estimates. Data presented includes all available survival information from Study GS-US-312-0116 (including data in long-term follow-up) and Study GS-US-312-0117 (including any data in long-term follow-up) up to the database finalization dates. Data from surviving participants were censored at the last time that the participant was known to be alive on study or long-term follow-up. Data presented includes all participants who were randomized to Study GS-US-312-0116 regardless if they entered Study GS-US-312-0117 or not.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Best Change From Baseline in Health-Related Quality of Life (HRQL) Domain and Symptom Scores Based on the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) Questionnaire
The FACT-Leu questionnaire included subscales for physical well-being (PWB, 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB, 6 items), functional well-being (FWB, 7 items), and additional concerns or Leukemia-Specific Subscale (LeuS, 17 items). The FACT-Leu scoring guide identified those negatively stated items that must have been reversed before being added to obtain subscale totals. Negatively stated items were reversed by subtracting the response from "4". After reversing proper items, all subscale items were summed to get total subscale scores with the range of 0-28, 0-28, 0-24, 0-28, 0-68 for PWB, SWB, EWB, FWB, and LeuS, respectively. FACT-Leu total score ranged from 0 to 176. Higher scores indicated a better quality of life. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.
Time frame: Study GS-US-312-0116 or GS-US-312-0117 Baseline up to Week 184
Best Change From Baseline in Karnofsky Performance Status (KPS)
KPS is a tool used to measure the ability to perform ordinary tasks. The score ranges from 0 to 100, with a higher score indicating that the participant is better able to carry out daily activities. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.
Time frame: Study GS-US-312-0116 or GS-US-312-0117 Baseline up to Week 190
Changes From Baseline in Phosphatidylinositol 3-kinase (PI3Kδ)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway Activation as a Measure of PI3Kδ Pathway Activity
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Overall Change From Baseline in the Plasma Concentrations of Disease-Associated Chemokines and Cytokines
The percent of average on-treatment biomarker concentration of baseline (%Baseline) was used to evaluate the overall pharmacodynamics change on the biomarkers with IDL treatment. The average on-treatment biomarker concentration is calculated using area under curve (AUC) following the trapezoidal rule. The biomarkers with median AUC value of 100 indicated no overall on-treatment biomarker changes compared to the baseline. The biomarkers with median AUC value greater than 100 or less than 100 indicated an increase or decrease, respectively, on-treatment biomarker changes from the baseline.
Time frame: GS-US-312-0116 Baseline to end of study GS-US-312-0117 (maximum: up to 67.6 months)
Study Drug Compliance as Assessed by the Percentage of Participants Adhering to Treatment
Adherence percentage was calculated as the sum of tablets dispensed - the sum of tablets returned divided by the sum of the overall dosing period (total daily tablets x dosing duration), taking into account investigator-prescribed interruptions.
Time frame: First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months)
Plasma Trough (Predose) and Peak (1.5 Hours Postdose) Concentrations of Idelalisib
Time frame: Weeks 4, 12, and 24
Change in Health Status as Assessed Using the EuroQoL Five-Dimension (EQ-5D) Utility Measure
Change in health status was defined as the change from baseline in overall health and single-item dimension scores as assessed using the EQ-5D utility measure. Percentage of participants with different level of problem were reported. Level 1: indicated no problem; Level 2: indicated some problems; and Level 3: indicated extreme problems. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.
Time frame: Study GS-US-312-0116 or GS-US-312-0117 Baseline; Weeks 24 and 48
Participants were enrolled at study sites in the United States and Europe. The first participant was screened on 03 October 2012. The last study visit occurred on 29 June 2018.
| Milestone | IDL+R to IDL 150 mg | IDL+R (PD) to IDL 300 mg | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|---|
| Started | 106 | 4 | 42 | 44 |
| Completed | 81 | 4 | 42 | 44 |
| Not completed | 25 | 0 | 0 | 0 |
| Withdrew: Adverse event | 9 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 12 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 |
| Milestone | IDL+R to IDL 150 mg | IDL+R (PD) to IDL 300 mg | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|---|
| Started | 71 | 4 | 42 | 44 |
| Completed | 30 | 2 | 20 | 18 |
| Not completed | 41 | 2 | 22 | 26 |
| Withdrew: Adverse event | 22 | 1 | 9 | 12 |
| Withdrew: Physician decision | 9 | 0 | 6 | 4 |
| Withdrew: Withdrawal by subject | 5 | 0 | 6 | 4 |
| Withdrew: Study terminated by sponsor | 3 | 0 | 0 | 5 |
| Withdrew: Other | 2 | 1 | 1 | 1 |
PFS was defined as the interval from the start of study therapy to the earlier of the first documentation of definitive disease progression or death from any cause; definitive disease progression is chronic lymphocytic leukemia (CLL) progression based on standard criteria other than lymphocytosis alone. PFS was analyzed using Kaplan-Meier (KM) estimates.
| months | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Progression-Free Survival (PFS) | 20.3 (17.3 to 26.3) | 6.9 (4.1 to 10.7) | 16.2 (8.8 to 26.2) |
The TEAEs were defined as events in a given study period that met one of the following criteria: * Events with onset dates on or after the start of treatment and up to 30 days after the permanent discontinuation of the study treatment. * The continuing adverse events (AEs) diagnosed prior to the start of treatment and worsened in severity grade, or non-serious AEs at baseline which became serious, or AEs resulting in treatment discontinuation after the start of treatment. The severity of AEs was graded by the investigator according to the common terminology criteria for adverse events (CTCAE), Version 4.03, whenever possible. The relationship of an AE to study drug (idelalisib) was assessed using clinical judgment by the investigator, describing the event as either unrelated or related. Events for which the investigator did not record relationship to study drug were considered related to study drug.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Any TEAE | 98.2 | 100.0 | 97.7 |
| ≥ Grade 3 TEAE | 90.9 | 88.1 | 90.9 |
| Study Drug-Related TEAE | 68.2 | 59.5 | 72.7 |
| ≥ Grade 3 Study Drug-Related TEAE | 47.3 | 45.2 | 45.5 |
| Serious TEAE | 80.9 | 81.0 | 72.7 |
| Study Drug-Related Serious TEAE | 35.5 | 26.2 | 29.5 |
| TEAE Leading to Study Drug Discontinuation | 47.3 | 64.3 | 50.0 |
ORR was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR). The determination of CLL response and progression were based on standardized International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs. CR and PR are defined in Protocol Amendment 9, Sections 7.5.1 and 7.5.2.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Overall Response Rate (ORR) | 85.5 (77.5 to 91.5) | 47.6 (32.0 to 63.6) | 68.2 (52.4 to 81.4) |
Lymph node response rate was defined as the percentage of participants who achieved a ≥ 50% decrease from baseline in the sum of the products of the greatest perpendicular diameters (SPD) of index lymph nodes.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Lymph Node Response Rate | 97.2 (92.0 to 99.4) | 77.8 (60.8 to 89.9) | 83.7 (69.3 to 93.2) |
CR rate was defined as the percentage of participants who achieved a CR (full definition in Protocol Amendment 9, Section 7.5.1). The determination of CLL response and progression were based on standardized IWCLL criteria, as specifically modified for this study to reflect current recommendations which considered the mechanism of action of idelalisib and similar drugs.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Complete Response (CR) Rate | 0.9 | 0.0 | 0.0 |
TTR was defined as the time interval from start of study therapy to the first documentation of CR or PR.
| months | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Time to Response (TTR) | 2.1 (1.9 to 3.8) | 3.6 (1.9 to 4.0) | 2.8 (1.9 to 4.2) |
DOR was defined as the time interval from the first documentation of CR or PR to the earlier of the first documentation of definitive disease progression or death from any cause. DOR was analyzed using KM estimates.
| months | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Duration of Response (DOR) | 21.4 (16.6 to 26.1) | 11.0 (3.3 to NA) | 17.6 (13.2 to 37.7) |
The best percent change from baseline in lymph node area (SPD) was defined as the largest decrease in tumor size during the study. The baseline SPD was the last value prior to the baseline reference date. For the participants who only had increases in tumor size from baseline, the smallest increase was considered as the best change from baseline in SPD.
| percent change | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Best Percent Change in Lymph Node Area | -80.1 (-86.1 to -70.5) | -69.7 (-79.5 to -53.7) | -71.4 (-80.4 to -62.7) |
Splenomegaly response rate was defined as the percentage of participants with baseline splenomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the enlargement of the splenic longest vertical dimension (LVD) (by imaging).
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Splenomegaly Response Rate | 80.3 (69.5 to 88.5) | 47.8 (26.8 to 69.4) | 66.7 (44.7 to 84.4) |
Hepatomegaly response rate was defined as the percentage of participants with baseline hepatomegaly who achieved an on-study normalization or a 50% decrease (minimum 2 cm) from baseline in the hepatic LVD (by imaging).
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Hepatomegaly Response Rate | 63.0 (48.7 to 75.7) | 36.4 (17.2 to 59.3) | 30.0 (11.9 to 54.3) |
ALC response rate was defined as the percentage of participants with baseline lymphocytosis (ALC ≥ 4 x 10\^9 cells/L) who achieved an on-study ALC \< 4 x 10\^9 cells/L or demonstrated a ≥ 50% decrease in ALC from baseline; ALC values within 4 weeks post-baseline were excluded from the ALC response rate evaluation.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Absolute Lymphocyte Count (ALC) Response Rate | 94.3 (87.2 to 98.1) | 66.7 (46.0 to 83.5) | 64.7 (46.5 to 80.3) |
Platelet response rate was defined as the percentage of participants with baseline thrombocytopenia (platelet count \< 100 x 10\^9/L) who achieved an on-study platelet count ≥ 100 x 10\^9/L or demonstrated a ≥ 50% increase in platelet count from baseline; platelet values within 4 weeks post-baseline or after 8 days post transfusion were excluded from the platelet response rate evaluation.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Platelet Response Rate | 98.0 (89.4 to 99.9) | 73.9 (51.6 to 89.8) | 100.0 (69.2 to 100.0) |
Hemoglobin response rate was defined as the percentage of participants with baseline anemia (hemoglobin \< 110 g/L \[11.0 g/dL\]) who achieved an on-study hemoglobin ≥ 110 g/L (11.0 g/dL) or demonstrated a ≥ 50% increase in hemoglobin from baseline; hemoglobin values within 4 weeks post-baseline or after 4 weeks of receiving packed cell/whole blood transfusion or after 6 weeks of receiving exogenous growth factors (eg, darbepoetin alfa) were excluded from the hemoglobin response evaluation.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Hemoglobin Response Rate | 83.1 (71.0 to 91.6) | 45.8 (25.6 to 67.2) | 81.8 (48.2 to 97.7) |
Neutrophil response rate was defined as the percentage of participants with baseline neutropenia (absolute neutrophil count \[ANC\] ≤ 1.5 x 10\^9/L) who achieved an ANC \> 1.5 x 10\^9/L or demonstrated a ≥ 50% increase in ANC from baseline; ANC values within 4 weeks of post-baseline or after 2 weeks of receiving exogenous growth factors (eg, filgrastim, granulocyte-colony stimulating factor \[G-CSF\], lenograstim) or after 4 weeks of receiving Neulasta® were excluded from response evaluation.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Neutrophil Response Rate | 96.3 (81.0 to 99.9) | 90.9 (58.7 to 99.8) | 100.0 (54.1 to 100.0) |
Overall survival was defined as the time interval from start of study therapy to death from any cause. Overall survival was analyzed using KM estimates. Data presented includes all available survival information from Study GS-US-312-0116 (including data in long-term follow-up) and Study GS-US-312-0117 (including any data in long-term follow-up) up to the database finalization dates. Data from surviving participants were censored at the last time that the participant was known to be alive on study or long-term follow-up. Data presented includes all participants who were randomized to Study GS-US-312-0116 regardless if they entered Study GS-US-312-0117 or not.
| months | IDL+R | Placebo+R |
|---|---|---|
| Overall Survival | 40.6 (28.5 to 57.3) | 34.6 (16.0 to NA) |
The FACT-Leu questionnaire included subscales for physical well-being (PWB, 7 items), social/family well-being (SWB, 7 items), emotional well-being (EWB, 6 items), functional well-being (FWB, 7 items), and additional concerns or Leukemia-Specific Subscale (LeuS, 17 items). The FACT-Leu scoring guide identified those negatively stated items that must have been reversed before being added to obtain subscale totals. Negatively stated items were reversed by subtracting the response from "4". After reversing proper items, all subscale items were summed to get total subscale scores with the range of 0-28, 0-28, 0-24, 0-28, 0-68 for PWB, SWB, EWB, FWB, and LeuS, respectively. FACT-Leu total score ranged from 0 to 176. Higher scores indicated a better quality of life. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.
| units on a scale | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Total Score: Baseline | 128.4 ± 22.72 | 116.7 ± 29.56 | 128.1 ± 29.16 |
| PWB: Baseline | 22.8 ± 4.42 | 20.2 ± 5.93 | 21.9 ± 5.41 |
| SWB: Baseline | 22.5 ± 5.53 | 22.5 ± 5.06 | 23.5 ± 5.04 |
| EWB: Baseline | 19.1 ± 3.44 | 17.3 ± 4.97 | 17.6 ± 4.48 |
| FWB: Baseline | 18.0 ± 6.57 | 15.0 ± 7.17 | 18.0 ± 6.88 |
| LeuS: Baseline | 46.0 ± 10.64 | 41.7 ± 12.74 | 47.0 ± 12.01 |
| Total Score: Best Change from Baseline | 21.8 ± 19.64 | 20.2 ± 19.91 | 14.9 ± 12.04 |
| PWB: Best Change from Baseline | 3.1 ± 4.65 | 3.6 ± 4.26 | 3.4 ± 3.81 |
| SWB: Best Change from Baseline | 2.9 ± 5.21 | 2.0 ± 2.88 | 2.1 ± 2.39 |
| EWB: Best Change from Baseline | 3.1 ± 2.75 | 3.1 ± 3.68 | 2.8 ± 3.14 |
| FWB: Best Change from Baseline | 5.1 ± 5.80 | 4.1 ± 5.01 | 3.1 ± 2.94 |
| LeuS: Best Change from Baseline | 11.3 ± 9.13 | 10.1 ± 8.78 | 7.8 ± 5.59 |
KPS is a tool used to measure the ability to perform ordinary tasks. The score ranges from 0 to 100, with a higher score indicating that the participant is better able to carry out daily activities. Best change from baseline was defined as the highest value of change from baseline among all postbaseline visits. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.
| units on a scale | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Baseline | 80.7 ± 12.47 | 78.1 ± 14.18 | 86.8 ± 8.83 |
| Best Change From Baseline | 11.1 ± 10.31 | 7.1 ± 8.67 | 4.3 ± 6.98 |
No measurements were reported for this outcome.
The percent of average on-treatment biomarker concentration of baseline (%Baseline) was used to evaluate the overall pharmacodynamics change on the biomarkers with IDL treatment. The average on-treatment biomarker concentration is calculated using area under curve (AUC) following the trapezoidal rule. The biomarkers with median AUC value of 100 indicated no overall on-treatment biomarker changes compared to the baseline. The biomarkers with median AUC value greater than 100 or less than 100 indicated an increase or decrease, respectively, on-treatment biomarker changes from the baseline.
| percentage of baseline | IDL/Placebo+R to IDL |
|---|---|
| Tumor Necrosis Factor (TNF)-alpha | 36.73 (5.34 to 183.56) |
| Macrophage Inflammatory Protein (MIP)1-alpha | 26.55 (3.76 to 236.22) |
| Interleukin (IL)-10 | 58.65 (2.36 to 1706.34) |
| IL-15 | 111.18 (51.28 to 230.1) |
| IL-12p40 | 64.89 (11.3 to 2012.31) |
| RANTES (CCL5) | 131.94 (6.76 to 3715.99) |
| IL-1ra | 114.22 (11.64 to 608.17) |
| Interferon (IFN)-gamma | 127.72 (10.55 to 4736.96) |
| C-Reactive Protein (CRP) | 132.38 (9.67 to 7625.53) |
| IFN-gamma-induced protein (IP)-10 (CXCL10) | 88.5 (15.24 to 786.21) |
| IL-7 | 91.82 (14.47 to 960.7) |
| Granulocyte-colony stimulating factor (G-CSF) | 96.59 (3.83 to 1586.48) |
| IL-17A | 100 (8.8 to 1311.69) |
| IL-6 | 100 (7.13 to 2817.44) |
| IL-8 | 102.59 (2.47 to 1724.25) |
Adherence percentage was calculated as the sum of tablets dispensed - the sum of tablets returned divided by the sum of the overall dosing period (total daily tablets x dosing duration), taking into account investigator-prescribed interruptions.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Adherence ≥ 75% | 100.0 | 97.6 | 100.0 |
| Adherence < 75% | 0.0 | 2.4 | 0.0 |
| ng/mL | IDL+R to IDL 150 mg | IDL+R (PD) to IDL 300 mg | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|---|
| Week 4: Predose | 384.0 (166.5 to 681.5) | 470.0 (317.0 to 631.0) | 301.5 (195.0 to 494.0) | 412.0 (211.0 to 646.0) |
| Week 4: 1.5 Hours Postdose | 2115.0 (1370.0 to 2750.0) | 3940.0 (1550.0 to 4000.0) | 2580.0 (1880.0 to 3080.0) | 1720.0 (1200.0 to 2660.0) |
| Week 12: Predose | 370.0 (196.0 to 745.0) | 570.0 (355.0 to 643.0) | 335.0 (190.0 to 470.0) | 298.0 (212.0 to 691.0) |
| Week 12: 1.5 Hours Postdose | 2110.0 (1595.0 to 2665.0) | 3800.0 (3160.0 to 4710.0) | 2245.0 (1655.0 to 3255.0) | 1940.0 (1430.0 to 2450.0) |
| Week 24: Predose | 307.0 (179.0 to 584.0) | 637.0 (524.0 to 930.0) | 362.0 (162.0 to 550.0) | 350.5 (261.0 to 504.5) |
| Week 24: 1.5 Hours Postdose | 2270.0 (1560.0 to 2790.0) | 5630.0 (5550.0 to 5660.0) | 2180.0 (1760.0 to 2980.0) | 2010.0 (1210.0 to 2430.0) |
Change in health status was defined as the change from baseline in overall health and single-item dimension scores as assessed using the EQ-5D utility measure. Percentage of participants with different level of problem were reported. Level 1: indicated no problem; Level 2: indicated some problems; and Level 3: indicated extreme problems. For participants who did not enter Study GS-US-312-0117, baseline values were from Study GS-US-312-0116.
| percentage of participants | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|
| Baseline: Anxiety/Depression, Level 1 | 70.4 | 50.0 | 56.8 |
| Baseline: Anxiety/Depression, Level 2 | 28.7 | 42.9 | 43.2 |
| Baseline: Anxiety/Depression, Level 3 | 0.9 | 7.1 | 0.0 |
| Baseline: Mobility, Level 1 | 60.2 | 38.1 | 61.4 |
| Baseline: Mobility, Level 2 | 39.8 | 59.5 | 38.6 |
| Baseline: Mobility, Level 3 | 0.0 | 2.4 | 0.0 |
| Baseline: Pain/Discomfort, Level 1 | 53.3 | 50.0 | 45.5 |
| Baseline: Pain/Discomfort, Level 2 | 39.3 | 45.2 | 50.0 |
| Baseline: Pain/Discomfort, Level 3 | 7.5 | 4.8 | 4.5 |
| Baseline: Self-Care, Level 1 | 90.7 | 76.2 | 84.1 |
| Baseline: Self-Care, Level 2 | 9.3 | 19.0 | 15.9 |
| Baseline: Self-Care, Level 3 | 0.0 | 4.8 | 0.0 |
| Baseline: Usual Activities, Level 1 | 56.5 | 28.6 | 52.3 |
| Baseline: Usual Activities, Level 2 | 36.1 | 52.4 | 45.5 |
| Baseline: Usual Activities, Level 3 | 7.4 | 19.0 | 2.3 |
| Week 24: Anxiety/Depression, Level 1 | 83.1 | 65.0 | 69.6 |
| Week 24: Anxiety/Depression, Level 2 | 15.6 | 35.0 | 30.4 |
| Week 24: Anxiety/Depression, Level 3 | 1.3 | 0.0 | 0.0 |
| Week 24: Mobility, Level 1 | 70.1 | 65.0 | 69.6 |
| Week 24: Mobility, Level 2 | 29.9 | 35.0 | 30.4 |
| Week 24: Mobility, Level 3 | 0.0 | 0.0 | 0.0 |
| Week 24: Pain/Discomfort, Level 1 | 62.3 | 65.0 | 43.5 |
| Week 24: Pain/Discomfort, Level 2 | 35.1 | 30.0 | 47.8 |
| Week 24: Pain/Discomfort, Level 3 | 2.6 | 5.0 | 8.7 |
| Week 24: Self-Care, Level 1 | 92.2 | 85.0 | 91.3 |
| Week 24: Self-Care, Level 2 | 6.5 | 15.0 | 8.7 |
| Week 24: Self-Care, Level 3 | 1.3 | 0.0 | 0.0 |
| Week 24: Usual Activities, Level 1 | 68.4 | 75.0 | 60.9 |
| Week 24: Usual Activities, Level 2 | 28.9 | 25.0 | 34.8 |
| Week 24: Usual Activities, Level 3 | 2.6 | 0.0 | 4.3 |
| Week 48: Anxiety/Depression, Level 1 | 84.1 | 90.0 | 50.0 |
| Week 48: Anxiety/Depression, Level 2 | 15.9 | 10.0 | 50.0 |
| Week 48: Anxiety/Depression, Level 3 | 0.0 | 0.0 | 0.0 |
| Week 48: Mobility, Level 1 | 72.7 | 60.0 | 66.7 |
| Week 48: Mobility, Level 2 | 27.3 | 40.0 | 33.3 |
| Week 48: Mobility, Level 3 | 0.0 | 0.0 | 0.0 |
| Week 48: Pain/Discomfort, Level 1 | 56.8 | 60.0 | 50.0 |
| Week 48: Pain/Discomfort, Level 2 | 43.2 | 30.0 | 50.0 |
| Week 48: Pain/Discomfort, Level 3 | 0.0 | 10.0 | 0.0 |
| Week 48: Self-Care, Level 1 | 95.5 | 90.0 | 83.3 |
| Week 48: Self-Care, Level 2 | 4.5 | 0.0 | 16.7 |
| Week 48: Self-Care, Level 3 | 0.0 | 10.0 | 0.0 |
| Week 48: Usual Activities, Level 1 | 72.7 | 70.0 | 50.0 |
| Week 48: Usual Activities, Level 2 | 25.0 | 20.0 | 33.3 |
| Week 48: Usual Activities, Level 3 | 2.3 | 10.0 | 16.7 |
Collected over Adverse Events: First IDL dose date in study GS-US-312-0116 or GS-US-312-0117 to last IDL dose date in study GS-US-312-0117 (maximum: 67.3 months) plus 30 days; All-Cause Mortality: First IDL dose date up to 67.6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDL+R to IDL 150 mg | 37/71 (52.1%) | 54/71 (76.1%) | 70/71 (98.6%) |
| IDL+R (PD) to IDL 300 mg | 3/4 (75%) | 2/4 (50%) | 4/4 (100%) |
| Placebo+R (PD) to IDL 150 mg | 25/42 (59.5%) | 34/42 (81%) | 41/42 (97.6%) |
| Placebo+R to IDL 150 mg | 16/44 (36.4%) | 32/44 (72.7%) | 43/44 (97.7%) |
| Event | IDL+R to IDL 150 mg | IDL+R (PD) to IDL 300 mg | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 6/71 | 2/4 | 10/42 | 3/44 |
| Sepsis pasteurellaInfections and infestations | 0/71 | 1/4 | 0/42 | 0/44 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/71 | 1/4 | 0/42 | 0/44 |
| Aortic aneurysmVascular disorders | 0/71 | 1/4 | 0/42 | 0/44 |
| HypotensionVascular disorders | 0/71 | 1/4 | 0/42 | 1/44 |
| DiarrhoeaGastrointestinal disorders | 7/71 | 0/4 | 4/42 | 8/44 |
| Febrile neutropeniaBlood and lymphatic system disorders | 4/71 | 0/4 | 5/42 | 1/44 |
| PyrexiaGeneral disorders | 4/71 | 0/4 | 1/42 | 4/44 |
| CellulitisInfections and infestations | 4/71 | 0/4 | 0/42 | 4/44 |
| ColitisGastrointestinal disorders | 5/71 | 0/4 | 1/42 | 3/44 |
| Event | IDL+R to IDL 150 mg | IDL+R (PD) to IDL 300 mg | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 30/71 | 2/4 | 17/42 | 26/44 |
| AnaemiaBlood and lymphatic system disorders | 8/71 | 2/4 | 5/42 | 4/44 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/71 | 2/4 | 3/42 | 4/44 |
| FatigueGeneral disorders | 15/71 | 2/4 | 13/42 | 9/44 |
| PyrexiaGeneral disorders | 17/71 | 0/4 | 12/42 | 16/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 21/71 | 0/4 | 12/42 | 16/44 |
| NauseaGastrointestinal disorders | 11/71 | 0/4 | 12/42 | 12/44 |
| NeutropeniaBlood and lymphatic system disorders | 14/71 | 1/4 | 9/42 | 6/44 |
| Abdominal distensionGastrointestinal disorders | 3/71 | 1/4 | 0/42 | 1/44 |
| Abdominal painGastrointestinal disorders | 8/71 | 1/4 | 5/42 | 5/44 |
Full Analysis Set included participants in the Intent-to-Treat (ITT) Analysis Set (all participants randomized in Study GS-US-312-0116) who received ≥ 1 dose of IDL, with treatment assignments designated according to randomization in Study GS-US-312-0116. Baseline data presented were collected at the beginning of Study GS-US-312-0116.
| Age, Customized(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| < 65 years | 21 | 13 | 10 | 44 |
| ≥ 65 years | 89 | 29 | 34 | 152 |
| Sex: Female, Male(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| Female | 34 | 11 | 18 | 63 |
| Male | 76 | 31 | 26 | 133 |
| Race/Ethnicity, Customized(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 3 | 1 | 1 | 5 |
| Ethnicity — Not Hispanic or Latino | 101 | 39 | 42 | 182 |
| Ethnicity — Not Permitted | 6 | 2 | 1 | 9 |
| Race/Ethnicity, Customized(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| Race — White | 100 | 37 | 40 | 177 |
| Race — Black or African American | 3 | 0 | 3 | 6 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Race — Asian | 0 | 0 | 0 | 0 |
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Other | 2 | 2 | 0 | 4 |
| Race — Not Permitted | 5 | 3 | 1 | 9 |
| Region of Enrollment(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| United States | 80 | 38 | 30 | 148 |
| United Kingdom | 18 | 3 | 6 | 27 |
| Italy | 2 | 1 | 4 | 7 |
| France | 3 | 0 | 1 | 4 |
| Germany | 7 | 0 | 3 | 10 |
| 17p Deletion and/or TP53 Mutation Status(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| Either | 46 | 21 | 14 | 81 |
| Neither | 64 | 21 | 30 | 115 |
| Immunoglobulin heavy chain variable region (IgHV) Mutation Status(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| Mutated | 19 | 6 | 7 | 32 |
| Unmutated | 91 | 36 | 37 | 164 |
| Karnofsky Performance Status (KPS)(Participants) | IDL+R to IDL | Placebo+R (PD) to IDL 150 mg | Placebo+R to IDL 150 mg | Total |
|---|---|---|---|---|
| KPS = 40 | 1 | 0 | 0 | 1 |
| KPS = 50 | 3 | 1 | 0 | 4 |
| KPS = 60 | 6 | 2 | 0 | 8 |
| KPS = 70 | 20 | 4 | 4 | 28 |
| KPS = 80 | 42 | 19 | 20 | 81 |
| KPS = 90 | 23 | 12 | 12 | 47 |
| KPS = 100 | 15 | 4 | 8 | 27 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
Ran from Oct 2012 to primary completion in May 2018, 67 months.
Results were first posted in Aug 2019, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Idelalisib
Leukemia, Lymphocytic, Chronic, B-Cell →